MCID: BRD004
MIFTS: 53

Borderline Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

MalaCards integrated aliases for Borderline Personality Disorder:

Name: Borderline Personality Disorder 12 74 54 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:10930
ICD9CM 34 301.83
MeSH 43 D001883
NCIt 49 C92633
SNOMED-CT 67 20010003
ICD10 32 F60.3
UMLS 71 C0006012

Summaries for Borderline Personality Disorder

Disease Ontology : 12 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary : Borderline Personality Disorder is related to avoidant personality disorder and impulse control disorder. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Dopamine and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and testes, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder (EUPD),... more...

Related Diseases for Borderline Personality Disorder

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 249)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 31.5 TPH1 SLC6A4 SLC6A3 MAOA HTR1B DRD2
2 impulse control disorder 31.4 SLC6A4 SLC6A3 MAOA HTR2A HTR1A DRD2
3 alexithymia 31.1 SLC6A4 HTR1A DRD2 COMT
4 dissociative disorder 31.0 SLC6A4 HTR2A FKBP5
5 obsessive-compulsive personality disorder 30.9 SLC6A4 HTR2A
6 intermittent explosive disorder 30.8 SLC6A4 MAOA HTR2A
7 somatization disorder 30.8 SLC6A4 HTR2A HTR1A CRH
8 body dysmorphic disorder 30.8 SLC6A4 MAOA HTR2A
9 dysthymic disorder 30.7 SLC6A4 MAOA HTR2A HTR1A CRH BDNF
10 traumatic brain injury 30.7 DRD2 COMT BDNF
11 acute stress disorder 30.7 SLC6A4 NR3C1 FKBP5 CRHR1 CRH BDNF
12 galactorrhea 30.7 PRL DRD2
13 cyclothymic disorder 30.6 HTR2A DRD2
14 agoraphobia 30.5 SLC6A4 MAOA HTR2A HTR1A COMT
15 conduct disorder 30.5 TPH1 SLC6A4 SLC6A3 MAOA DRD2 COMT
16 brain injury 30.5 DRD2 COMT BDNF
17 antisocial personality disorder 30.5 SLC6A4 SLC6A3 PRL MAOA HTR2A HTR1B
18 neurotic disorder 30.4 SLC6A4 MAOA HTR2A HTR1A BDNF
19 amnestic disorder 30.4 HTR3A HTR1A DRD2 BDNF
20 phobia, specific 30.4 SLC6A4 MAOA HTR1A COMT
21 somatoform disorder 30.4 TPH1 SLC6A4 HTR3A COMT BDNF
22 adjustment disorder 30.4 SLC6A4 HTR2A BDNF
23 polysubstance abuse 30.3 DRD2 COMT
24 depression 30.3 TPH2 SLC6A4 MAOA HTR2C HTR2A HTR1A
25 paine syndrome 30.3 HTR3A COMT BDNF
26 tardive dyskinesia 30.2 HTR2A DRD2 COMT
27 hypochondriasis 30.2 SLC6A4 HTR3A HTR2A HTR1A BDNF
28 schizoaffective disorder 30.2 SLC6A4 PRL HTR2A HTR1A DRD2 COMT
29 opioid addiction 30.1 DRD2 COMT
30 heroin dependence 30.0 SLC6A4 SLC6A3 MAOA DRD2 COMT BDNF
31 oppositional defiant disorder 30.0 TPH2 SLC6A4 SLC6A3 MAOA DRD2 COMT
32 asperger syndrome 30.0 SLC6A4 COMT BDNF AVPR1A
33 sleep apnea 30.0 SLC6A4 HTR2C HTR2A BDNF
34 withdrawal disorder 29.9 DRD2 CRHR1 CRH
35 postpartum depression 29.9 SLC6A4 PRL MAOA HTR1A CRH COMT
36 schizophreniform disorder 29.9 PRL HTR2A DRD2 COMT BDNF
37 eating disorder 29.9 SLC6A4 SLC6A3 HTR2C HTR2A DRD2 CRHR2
38 social phobia 29.9 SLC6A4 PRL MAOA HTR3A HTR1A DRD2
39 hyperprolactinemia 29.8 PRL HTR2C HTR2A DRD2
40 anorexia nervosa 29.8 SLC6A4 PRL MAOA HTR2C HTR2A HTR1A
41 melancholia 29.8 SLC6A4 PRL MAOA HTR2A HTR1A CRH
42 bipolar i disorder 29.7 TPH2 SLC6A4 HTR2C HTR2A HTR1A DRD2
43 substance-induced psychosis 29.7 SLC6A3 HTR2A HTR1A DRD2 COMT
44 anterograde amnesia 29.7 HTR1A BDNF
45 post-traumatic stress disorder 29.7 SLC6A4 NR3C1 MAOA HTR2A FKBP5 DRD2
46 opiate dependence 29.7 TPH1 SLC6A4 SLC6A3 DRD2 CRH
47 sleep disorder 29.6 SLC6A4 SLC6A3 PRL HTR2C HTR2A HTR1A
48 fibromyalgia 29.6 SLC6A4 HTR3A HTR2A DRD2 CRH COMT
49 delusional disorder 29.5 SLC6A3 HTR2C HTR2A HTR1A DRD2
50 dementia 29.5 SLC6A3 MAOA HTR2A HTR1A DRD2 COMT

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Cerebral Atherosclerosis Dependent Personality Disorder
Dysthymic Disorder Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to Borderline Personality Disorder

Symptoms & Phenotypes for Borderline Personality Disorder

GenomeRNAi Phenotypes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Borderline Personality Disorder:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.51 AVPR1A BDNF COMT CRH CRHR1 CRHR2
2 homeostasis/metabolism MP:0005376 10.41 AVPR1A BDNF COMT CRH CRHR1 CRHR2
3 endocrine/exocrine gland MP:0005379 10.32 AVPR1A BDNF COMT CRH CRHR1 CRHR2
4 cardiovascular system MP:0005385 10.27 AVPR1A COMT CRHR1 CRHR2 DRD2 HTR1A
5 nervous system MP:0003631 10.24 AVPR1A BDNF COMT CRH CRHR1 DRD2
6 integument MP:0010771 10.17 BDNF CRH DRD2 HTR2C HTR3A NR3C1
7 adipose tissue MP:0005375 10.13 CRH CRHR2 DRD2 HTR1B HTR2C NR3C1
8 muscle MP:0005369 10.1 AVPR1A DRD2 HTR1B HTR2A HTR2C HTR3A
9 normal MP:0002873 9.96 AVPR1A BDNF CRH CRHR1 DRD2 FKBP5
10 no phenotypic analysis MP:0003012 9.92 BDNF CRH CRHR1 DRD2 HTR1A HTR1B
11 reproductive system MP:0005389 9.81 BDNF COMT DRD2 FKBP5 HTR1B HTR3A
12 respiratory system MP:0005388 9.56 BDNF COMT CRH CRHR1 DRD2 NR3C1
13 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Borderline Personality Disorder

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Citalopram Approved Phase 4 59729-33-8 2771
3
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
7 Omega 3 Fatty Acid Phase 4
8 Neurotransmitter Agents Phase 4
9 Dopamine Agents Phase 4
10 Serotonin Agents Phase 4
11 Serotonin Uptake Inhibitors Phase 4
12 Autonomic Agents Phase 4
13 Antiparkinson Agents Phase 4
14 Cholinergic Agents Phase 4
15 Parasympatholytics Phase 4
16 Muscarinic Antagonists Phase 4
17 Cholinergic Antagonists Phase 4
18 Sodium Channel Blockers Phase 4
19 Calcium, Dietary Phase 4
20 calcium channel blockers Phase 4
21 Diuretics, Potassium Sparing Phase 4
22 Dopamine Antagonists Phase 4
23 Serotonin Antagonists Phase 4
24 Cytochrome P-450 Enzyme Inhibitors Phase 4
25 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
26
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
27
Rifaximin Approved, Investigational Phase 2, Phase 3 80621-81-4 6436173 46783403
28
Olanzapine Approved, Investigational Phase 3 132539-06-1 4585
29
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 26757 5195
30
Brexpiprazole Approved, Investigational Phase 2, Phase 3 913611-97-9 11978813
31
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
32 Antitubercular Agents Phase 2, Phase 3
33 Anti-Bacterial Agents Phase 2, Phase 3
34 Antibiotics, Antitubercular Phase 2, Phase 3
35 Sulfalene Phase 2, Phase 3
36 Antiemetics Phase 3
37 Gastrointestinal Agents Phase 3
38 Tranquilizing Agents Phase 3
39 Quetiapine Fumarate Phase 3 111974-72-2
40 Dopamine agonists Phase 2, Phase 3
41 Narcotics Phase 3
42 Analgesics, Opioid Phase 3
43 Narcotic Antagonists Phase 3
44
Acetaminophen Approved Phase 2 103-90-2 1983
45
Ziprasidone Approved Phase 2 146939-27-7 60854
46
Lithium carbonate Approved Phase 2 554-13-2
47
Cocaine Approved, Illicit Phase 2 50-36-2 5760 446220
48
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
49
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
50
Midazolam Approved, Illicit Phase 2 59467-70-8 4192

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
3 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder: The UAB Borderline Rating Scale (BRS) Completed NCT00204347 Phase 4 risperidone
4 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
5 Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
6 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
7 Effect of Probiotics on Central Nervous System Functions in Humans Unknown status NCT02793193 Phase 2, Phase 3 Antibiotic
8 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo Completed NCT00088036 Phase 3 Olanzapine
9 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo Completed NCT00091650 Phase 3 Olanzapine;placebo
10 BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder Completed NCT00538135 Phase 3
11 A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
12 Seroquel XR for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
13 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
14 Short-term Versus Long-term Mentalization-based Therapy for Outpatients With Subthreshold or Diagnosed Borderline Personality Disorder: a Randomized Clinical Trial Recruiting NCT03677037 Phase 3
15 A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder Not yet recruiting NCT04186403 Phase 2, Phase 3 Brexpiprazole
16 Evaluation of the Efficacy of the Opioid Antagonist Naltrexone on the Incidence and Intensity of Flashbacks and Dissociative States in Patients With Borderline Personality Disorder Terminated NCT00124839 Phase 3 Naltrexone
17 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3 Topiramate
18 Acetaminophen and Social Pain in Borderline Personality Disorder Unknown status NCT02108990 Phase 2 Acetaminophen
19 The Efficacy of a Cognitive-Behavioural Intervention in Deliberate Self-Harm Patients: A Randomized Controlled Trial Among Adolescents and Young Adults Unknown status NCT00169884 Phase 2
20 Pilot Study of Central Meditation and Imagery Therapy for Borderline Personality Disorder Completed NCT02125942 Phase 1, Phase 2
21 The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial Completed NCT00254748 Phase 2 Quetiapine fumarate;Placebo
22 Assessment and Treatment of Parasuicidal Patients Completed NCT00183651 Phase 2
23 Ziprasidone in the Treatment of Borderline Personality Disorder: A Double-Blind, Placebo-Controlled, Randomized Study Completed NCT00635921 Phase 2 ziprasidone;Placebo
24 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2 Naltrexone;Placebo
25 Psychodynamic Therapy for Patients With Borderline Personality Disorder and Alcohol Abuse Completed NCT00145678 Phase 2
26 Treating PTSD in Patients With Borderline Personality Disorder Completed NCT01081314 Phase 1, Phase 2
27 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Assess the Safety and Efficacy of Citalopram in Combination With Lithium or Placebo in the Treatment of Symptoms in Patients With Depressive Mood Disorders Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
28 Cognitive Behavioral Therapy for PTSD in Addiction Treatment: A Randomized Pilot Trial Completed NCT01456338 Phase 2
29 The Use of Oxytocin as Adjunctive Therapy for the Treatment of Schizophrenia: a Randomized, Double Blind Trial Completed NCT01699997 Phase 2 Oxytocin;Placebo
30 Cognitive Therapy for PTSD in Addiction Treatment Completed NCT00685451 Phase 1, Phase 2
31 A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder Recruiting NCT04100096 Phase 2 Brexpiprazole
32 Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) Recruiting NCT02728778 Phase 2 incobotulinumtoxin A
33 A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder. Recruiting NCT03418675 Phase 2 Rexulti;Placebo
34 A Randomised Double-blind Placebo Controlled Investigation of the Efficacy of a Novel Drug as an Adjunct in Patients With Borderline Personality Disorder Recruiting NCT02097706 Phase 2 NMDA receptor antagonist (active drug)
35 A Randomized Active Placebo Controlled Trial of Ketamine in Borderline Personality Disorder Recruiting NCT03395314 Phase 2 Ketamine;Midazolam
36 Dialectical Behavior Therapy (DBT) for Adolescents With Bipolar Disorder Recruiting NCT02003690 Phase 2 Pharmacotherapy
37 Investigating the Impact of Oxytocin on Irritability/Emotional Dysregulation in Children and Adolescents With Disruptive Behavior and Mood Disorders, and the Possible Mediating Role of Amygdala Activity Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
38 Multimodal Study of the Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder : Stress Reactivity and Functional Imaging Not yet recruiting NCT03209102 Phase 2
39 SSRIs and Self-harm in Borderline Personality Disorder Terminated NCT01103180 Phase 2 Escitalopram
40 Preliminary, Double Blind, Placebo Controlled Trial of the Effect of Glucocorticoid Receptor Antagonist Treatment on Biologic and Symptom Outcomes in Patients With Borderline Personality Disorder and Histories of Childhood Abuse Terminated NCT01212588 Phase 2 mifepristone;Placebo
41 A Double-Blind, Placebo-controlled Pilot Study of NAC Addition to Dialectical Behavioral Therapy for the Treatment of Self-Injurious Behavior Associated With Borderline Personality Disorder Terminated NCT00539188 Phase 2 N-Acetylcysteine;placebo
42 Creativity Group for Borderline Personality Disorder Unknown status NCT01343550 Phase 1
43 Study of Outcome With an Intervention From the Cape Cod Model of Psychotherapy for Subjects in a Behavioral Crisis and With the Diagnosis of Borderline Personality Disorder (BPD) or Post-Traumatic Stress Disorder (PTSD) Unknown status NCT00269139 Phase 1
44 Evaluating the Effectiveness of Dialectical Behaviour Skills Training for Suicidality in Borderline Personality Disorder Completed NCT01193205 Phase 1
45 N-Acetylcysteine in the Treatment of Deliberate Self-Harm in Adolescents: An Open Label Pilot Study Completed NCT01111734 Phase 1 fMRI
46 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Recruiting NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
47 Effect of Fish Oil vs. Placebo on Subjective Effects of Alcohol in Healthy Humans Recruiting NCT03010917 Phase 1 Fish Oil with ethanol and placebo ethanol infusions;Placebo with ethanol and placebo ethanol infusions
48 Dialectical Behavioral Therapy for Patients With Borderline Personality Disorder Unknown status NCT00252031
49 Emotional Reaction of Patients With Borderline Personality Disorder (BPD)on Stimuli Connected to Self-injury - A Comparison Between Patients With BPD and a Healthy Control Group. Unknown status NCT03149926
50 A Sham-controlled Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Patients Unknown status NCT01602497

Search NIH Clinical Center for Borderline Personality Disorder

Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

Anatomical Context for Borderline Personality Disorder

MalaCards organs/tissues related to Borderline Personality Disorder:

40
Brain, Pituitary, Testes, Amygdala, Cortex, Skin, Eye

Publications for Borderline Personality Disorder

Articles related to Borderline Personality Disorder:

(show top 50) (show all 6073)
# Title Authors PMID Year
1
Association analysis between gene variants of the tyrosine hydroxylase and the serotonin transporter in borderline personality disorder. 54 61
20146650 2010
2
In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. 54 61
19523495 2009
3
Interaction between gene variants of the serotonin transporter promoter region (5-HTTLPR) and catechol O-methyltransferase (COMT) in borderline personality disorder. 54 61
18756498 2009
4
Serotonin transporter polymorphism and fluoxetine effect on impulsiveness and aggression in borderline personality disorder. 54 61
17597424 2007
5
Association between the serotonin transporter gene and personality traits in borderline personality disorder patients evaluated with Zuckerman-Zuhlman Personality Questionnaire (ZKPQ). 54 61
18004675 2007
6
Monoamine oxidase a gene is associated with borderline personality disorder. 54 61
17417058 2007
7
[Personality disorders in a nonclinical sample of adolescents]. 54 61
12506264 2002
8
How do I want to feel? The link between emotion goals and difficulties in emotion regulation in borderline personality disorder. 61
31553067 2020
9
Implicitly measured aggressiveness self-concepts in women with borderline personality disorder as assessed by an Implicit Association Test. 61
31539707 2020
10
Prevalence and clinical characterisation of pregnant women with eating disorders. 61
31989719 2020
11
Covariates of the Severity of Aggression in Sexual Crimes: Psychopathy and Borderline Characteristics. 61
30394860 2020
12
Pathoetiology and pathophysiology of borderline personality: Role of prenatal factors, gut microbiome, mu- and kappa-opioid receptors in amygdala-PFC interactions. 61
31689444 2020
13
Inflammatory and antioxidant pathway dysfunction in borderline personality disorder. 61
31955054 2020
14
Altered psychophysiological correlates of risk-taking in borderline personality disorder. 61
32011003 2020
15
SERT and BDNF polymorphisms interplay on neuroticism in borderline personality disorder. 61
32033618 2020
16
Borderline personality disorder, complex trauma, and problems with self and identity: A social-communicative approach. 61
31066053 2020
17
Alterations in the fronto-limbic network and corpus callosum in borderline-personality disorder. 61
31877433 2020
18
Associations between infant and toddler regulatory problems, childhood co-developing internalising and externalising trajectories, and adolescent depression, psychotic and borderline personality disorder symptoms. 61
31469175 2020
19
Common and distinct brain functional alterations in pharmacotherapy treatment-naïve female borderline personality disorder patients with and without auditory verbal hallucinations: a pilot study. 61
32009225 2020
20
Severity of borderline personality disorder symptoms as a moderator of the association between the use of dialectical behaviour therapy skills and treatment outcomes. 61
32013808 2020
21
Standalone DBT Group Skills Training Versus Standard (i.e. All Modes) DBT for Borderline Personality Disorder: A Natural Quasi-experiment in Routine Clinical Practice. 61
31673877 2020
22
Mechanisms of change in dialectical behaviour therapy and cognitive behaviour therapy for borderline personality disorder: a critical review of the literature. 61
28480806 2020
23
The reciprocal impacts of adversity and personality traits: A prospective longitudinal study of growth, change, and the power of personality. 61
32031239 2020
24
Romantic attachment style and borderline personality pathology: A meta-analysis. 61
31918217 2020
25
Alterations of social attention in mental disorders: Phenomenology, scope, and future directions for research. 61
32032824 2020
26
Outcomes for 18 to 25-year-olds with borderline personality disorder in a dedicated young adult only DBT programme compared to a general adult DBT programme for all ages 18. 61
31044536 2020
27
Internalized stigmatization in borderline personality disorder and attention deficit hyperactivity disorder in comparison to bipolar disorder. 61
31733922 2020
28
The effect of Clinical Practice Guidelines on prescribing practice in mental health: A systematic review. 61
31732189 2020
29
Specific or transdiagnostic? The occurrence of emotions and their association with distress in the daily life of patients with borderline personality disorder compared to clinical and healthy controls. 61
31784065 2020
30
Childhood maltreatment, anxiety disorders and outcome in borderline personality disorder. 61
31784066 2020
31
The subjective-agentic personality sector (SAPS): Introduction to the special issue on self, identity, and psychopathology. 61
31206666 2020
32
Differentiating borderline personality disorder (BPD) from bipolar disorder: diagnostic efficiency of DSM BPD criteria. 61
31758547 2020
33
[Exploring Early Maladaptative Schema (EMS) in adults with bipolar disorder: A systematic review of the scientific literature]. 61
31767255 2020
34
Development of an early intervention programme for adolescents with emotion dysregulation and their families: Actions for the treatment of adolescent personality (ATraPA). 61
32026614 2020
35
The moderating role of dissociation in the relation between borderline features and factors of self-injury in adolescents. 61
32026619 2020
36
Unextracted plasma oxytocin levels decrease following in-laboratory social exclusion in young adults with a suicide attempt history. 61
31835187 2020
37
Antisocial and borderline personality disorders in the offspring of antenatally depressed mothers - a follow-up until mid-adulthood in the Northern Finland 1966 birth cohort. 61
31647361 2020
38
Adaptive family functioning and borderline personality disorder: Mediating role of impulsivity. 61
31954029 2020
39
Parameters of reported childhood sexual abuse and assault in adolescents and adults with borderline personality disorder. 61
31960623 2020
40
Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? 61
31693423 2020
41
Psychotherapies for Adolescents with Subclinical and Borderline Personality Disorder: A Systematic Review and Meta-Analysis. 61
31558033 2020
42
Differential effects of the menstrual cycle on reactive and proactive aggression in borderline personality disorder. 61
31957896 2020
43
Interpersonal Functioning in Borderline Personality Disorder Traits: A Social Media Perspective. 61
31974517 2020
44
Effectiveness of an Emotional Working Memory Training in Borderline Personality Disorder: A Proof-of-Principle Study. 61
31901902 2020
45
[Are Especially Patients with Borderline Personality Disorder Stigmatised by Psychiatric Nurses?] 61
31910459 2020
46
A network analysis of borderline personality disorder symptoms and disordered eating. 61
31953849 2020
47
Rejection sensitivity in borderline personality disorder and the cognitive-affective personality system: A meta-analytic review. 61
31478717 2020
48
Emotion dysregulation and resting-state autonomic function in adolescent borderline personality disorder-A multimodal assessment approach. 61
31670544 2020
49
Treatment for Borderline Personality Disorder and Secondary Effects on Somatization. 61
31990615 2020
50
Childhood adversity and borderline personality disorder: a meta-analysis. 61
31630389 2020

Variations for Borderline Personality Disorder

Expression for Borderline Personality Disorder

Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for Borderline Personality Disorder

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.46 PRL NR3C1 HTR2C HTR2A HTR1B HTR1A
2
Show member pathways
12.94 HTR2C HTR2A DRD2 CRHR2 CRHR1 CRH
4 12.18 HTR1B HTR1A DRD2 BDNF
5 12.12 TPH2 TPH1 SLC6A4 NR3C1 MAOA HTR3A
6
Show member pathways
11.91 SLC6A3 MAOA DRD2 BDNF
7 11.87 TPH2 TPH1 SLC6A4 MAOA HTR3A HTR2C
8
Show member pathways
11.81 HTR2C HTR2A HTR1B HTR1A DRD2
9 11.74 CRHR2 CRHR1 CRH
10
Show member pathways
11.72 TPH2 TPH1 MAOA
11 11.7 HTR2C HTR2A DRD2
12
Show member pathways
11.67 TPH2 TPH1 MAOA
13 11.65 PRL NR3C1 FKBP5
14
Show member pathways
11.39 TPH2 SLC6A4 SLC6A3 MAOA
15
Show member pathways
11.04 SLC6A4 SLC6A3 MAOA COMT
16
Show member pathways
11.03 TPH1 MAOA COMT
17 10.97 PRL HTR2C DRD2
18
Show member pathways
10.92 TPH2 SLC6A4 SLC6A3 MAOA HTR1B HTR1A
19
Show member pathways
10.78 MAOA COMT
20 10.74 MAOA COMT
21 10.72 TPH2 TPH1 SLC6A4 MAOA HTR3A HTR2C
22 10.43 CRHR2 CRHR1 CRH

GO Terms for Borderline Personality Disorder

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.25 SLC6A4 SLC6A3 MAOA HTR3A HTR2C HTR2A
2 integral component of plasma membrane GO:0005887 10 SLC6A4 SLC6A3 HTR3A HTR2C HTR2A HTR1B
3 axon GO:0030424 9.87 SLC6A3 HTR3A HTR2A DRD2 CRHR2 COMT
4 neuron projection GO:0043005 9.8 TPH2 TPH1 SLC6A4 SLC6A3 HTR3A
5 dendrite GO:0030425 9.76 HTR2C HTR2A HTR1B HTR1A DRD2 CRHR2
6 dopaminergic synapse GO:0098691 9.46 SLC6A3 DRD2
7 serotonergic synapse GO:0099154 9.37 SLC6A4 HTR1B
8 integral component of postsynaptic membrane GO:0099055 9.35 SLC6A4 SLC6A3 HTR3A HTR2A DRD2
9 integral component of presynaptic membrane GO:0099056 9.1 SLC6A4 SLC6A3 HTR3A HTR2A HTR1B DRD2

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.13 PRL NR3C1 HTR3A HTR2C HTR2A HTR1B
2 G protein-coupled receptor signaling pathway GO:0007186 10.11 HTR2C HTR2A HTR1B HTR1A DRD2 CRHR2
3 positive regulation of cell proliferation GO:0008284 10.09 PRL HTR2A HTR1A CRH AVPR1A
4 chemical synaptic transmission GO:0007268 9.88 HTR3A HTR2C HTR2A HTR1B HTR1A CRH
5 locomotory behavior GO:0007626 9.86 SLC6A3 HTR2C DRD2
6 circadian rhythm GO:0007623 9.86 TPH2 TPH1 SLC6A4
7 memory GO:0007613 9.85 SLC6A4 HTR2A BDNF
8 female pregnancy GO:0007565 9.83 PRL CRHR1 CRH COMT
9 response to estrogen GO:0043627 9.82 TPH2 CRH COMT
10 release of sequestered calcium ion into cytosol GO:0051209 9.81 HTR2C HTR2A DRD2
11 regulation of synaptic vesicle exocytosis GO:2000300 9.81 HTR2A HTR1B DRD2
12 positive regulation of fat cell differentiation GO:0045600 9.8 TPH1 HTR2C HTR2A
13 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.78 HTR2C HTR2A HTR1B HTR1A
14 response to ethanol GO:0045471 9.77 SLC6A3 HTR3A HTR1B DRD2 CRH
15 regulation of dopamine secretion GO:0014059 9.76 HTR2A HTR1B DRD2
16 feeding behavior GO:0007631 9.75 HTR2C HTR1B DRD2
17 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.74 HTR2A HTR1B HTR1A
18 activation of phospholipase C activity GO:0007202 9.73 HTR2A BDNF AVPR1A
19 bone remodeling GO:0046849 9.71 TPH1 HTR1B
20 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 DRD2 CRHR1
21 prepulse inhibition GO:0060134 9.7 SLC6A3 DRD2
22 dopamine metabolic process GO:0042417 9.7 DRD2 COMT
23 neurotransmitter biosynthetic process GO:0042136 9.7 SLC6A4 SLC6A3
24 positive regulation of renal sodium excretion GO:0035815 9.7 DRD2 AVPR1A
25 grooming behavior GO:0007625 9.69 DRD2 AVPR1A
26 G protein-coupled receptor internalization GO:0002031 9.69 HTR1B DRD2
27 vasoconstriction GO:0042310 9.69 SLC6A4 HTR1B HTR1A
28 regulation of behavior GO:0050795 9.68 HTR1B HTR1A
29 neurotransmitter catabolic process GO:0042135 9.67 MAOA COMT
30 regulation of dopamine metabolic process GO:0042053 9.67 SLC6A3 HTR1A
31 parturition GO:0007567 9.67 CRHR1 CRH
32 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.67 HTR2A HTR1B DRD2
33 catecholamine metabolic process GO:0006584 9.66 MAOA COMT
34 adenohypophysis development GO:0021984 9.66 SLC6A3 DRD2
35 monoamine transport GO:0015844 9.65 SLC6A4 SLC6A3
36 aromatic amino acid family metabolic process GO:0009072 9.65 TPH2 TPH1
37 drinking behavior GO:0042756 9.65 HTR1B DRD2
38 cellular response to corticotropin-releasing hormone stimulus GO:0071376 9.62 CRHR2 CRHR1
39 indolalkylamine biosynthetic process GO:0046219 9.62 TPH2 TPH1
40 sperm ejaculation GO:0042713 9.61 SLC6A4 AVPR1A
41 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.61 HTR1B HTR1A
42 dopamine catabolic process GO:0042420 9.61 SLC6A3 MAOA COMT
43 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.6 HTR2C HTR2A
44 serotonin biosynthetic process GO:0042427 9.59 TPH2 TPH1
45 behavior GO:0007610 9.56 HTR2C HTR2A HTR1B HTR1A
46 regulation of serotonin secretion GO:0014062 9.55 HTR1A CRH
47 response to cocaine GO:0042220 9.55 SLC6A3 HTR3A HTR1B DRD2 CRH
48 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.54 HTR2C HTR2A
49 serotonin receptor signaling pathway GO:0007210 9.26 HTR3A HTR2C HTR2A HTR1A
50 response to drug GO:0042493 9.23 SLC6A4 SLC6A3 HTR2C HTR2A HTR1B DRD2

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.46 SLC6A4 SLC6A3 PRL NR3C1 MAOA HTR3A
2 G protein-coupled receptor activity GO:0004930 9.92 HTR2C HTR2A HTR1B HTR1A DRD2 CRHR2
3 peptide hormone binding GO:0017046 9.67 CRHR2 CRHR1 AVPR1A
4 neurotransmitter receptor activity GO:0030594 9.56 HTR2C HTR2A HTR1B HTR1A
5 neurotransmitter:sodium symporter activity GO:0005328 9.55 SLC6A4 SLC6A3
6 dopamine binding GO:0035240 9.54 SLC6A3 DRD2
7 monoamine transmembrane transporter activity GO:0008504 9.52 SLC6A4 SLC6A3
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.48 TPH2 TPH1
9 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.46 HTR2C HTR2A
10 G protein-coupled serotonin receptor activity GO:0004993 9.46 HTR2C HTR2A HTR1B HTR1A
11 corticotropin-releasing hormone receptor activity GO:0043404 9.43 CRHR2 CRHR1
12 corticotrophin-releasing factor receptor activity GO:0015056 9.4 CRHR2 CRHR1
13 tryptophan 5-monooxygenase activity GO:0004510 9.37 TPH2 TPH1
14 drug binding GO:0008144 9.35 SLC6A3 HTR2C HTR2A HTR1B DRD2
15 serotonin binding GO:0051378 9.1 SLC6A4 HTR3A HTR2C HTR2A HTR1B HTR1A

Sources for Borderline Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....